Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes

We discuss the multivariate (2 L -variate) correlation structure and the asymptotic distribution for the group-sequential weighted logrank statistics formulated when monitoring two correlated event-time outcomes in clinical trials. The asymptotic distribution and the variance–covariance for the 2 L -variate weighted logrank statistic are derived as available in various group-sequential trial designs. These methods are used to determine a group-sequential testing procedure based on calendar times or information fractions. We apply the theoretical results to a group-sequential method for monitoring a clinical trial with early stopping for efficacy when the trial is designed to evaluate the joint effect on two correlated event-time outcomes. We illustrate the method with application to a clinical trial and describe how to calculate the required sample sizes and numbers of events.

[1]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[2]  Anastasios A. Tsiatis,et al.  Group sequential methods for survival analysis with staggered entry , 1982 .

[3]  David W. Haas,et al.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. , 2014, Annals of internal medicine.

[4]  Edit Gombay.  Weighted Logrank Statistics in Sequential Tests , 2008 .

[5]  Toshimitsu Hamasaki,et al.  Sizing clinical trials when comparing bivariate time‐to‐event outcomes , 2017, Statistics in medicine.

[6]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[7]  Jianwen Cai,et al.  Covariance and survivor function estimation using censored multivariate failure time data , 1992 .

[8]  Susan Murray,et al.  Simultaneous Group Sequential Analysis of Rank‐Based and Weighted Kaplan–Meier Tests for Paired Censored Survival Data , 2005, Biometrics.

[9]  Toshimitsu Hamasaki,et al.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes , 2015, Statistics in biopharmaceutical research.

[10]  Susanne M Arnold,et al.  Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. , 2018, The Lancet. Oncology.

[11]  S Murray,et al.  Nonparametric Rank‐Based Methods for Group Sequential Monitoring of Paired Censored Survival Data , 2000, Biometrics.

[12]  David W. Haas,et al.  A Phase III Comparative Study of the Efficacy and Tolerability of Three Non-Nucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naïve HIV-1-Infected Volunteers: A Randomized, Controlled Trial , 2014 .

[13]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[14]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[15]  P. Hougaard.  A class of multivanate failure time distributions , 1986 .

[16]  Dorota M. Dabrowska,et al.  Kaplan-Meier Estimate on the Plane , 1988 .

[17]  Xiaoping Xiong,et al.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test , 2017, Statistics in biopharmaceutical research.

[18]  Meinhard Kieser,et al.  Adaptive Designs for Two Candidate Primary Time-to-Event Endpoints , 2016 .

[19]  Robert L. Strawderman,et al.  A note on the Breslow survival estimator , 2006 .

[20]  D. Clayton.  A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[21]  Kenichi Hayashi,et al.  Sample size determination in group‐sequential clinical trials with two co‐primary endpoints , 2014, Statistics in medicine.

[22]  Anastasios A. Tsiatis,et al.  Sequential methods for parametric survival models , 1995 .

[23]  Rebecca Finch,et al.  Multiple testing problems in pharmaceutical statistics. , 2014, Pharmaceutical statistics.

[24]  Cyrus R Mehta,et al.  Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. , 2012, Statistics in medicine.

[25]  Eric V. Slud,et al.  Two-Sample Repeated Significance Tests Based on the Modified Wilcoxon Statistic , 1982 .

[26]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[27]  Frank Bretz,et al.  Hierarchical testing of multiple endpoints in group‐sequential trials , 2010, Statistics in medicine.

[28]  Lingyun Liu,et al.  Testing a Primary and a Secondary Endpoint in a Group Sequential Design , 2010, Biometrics.

[29]  J M Lachin,et al.  Implementation of group sequential logrank tests in a maximum duration trial. , 1990, Biometrics.

[30]  N E Breslow,et al.  Group sequential designs for monitoring survival probabilities. , 1996, Biometrics.

[31]  Nancy L. Geller,et al.  Design of Group Sequential Clinical Trials with Multiple Endpoints , 1989 .

[32]  Sin-Ho Jung,et al.  Sample size calculation for the weighted rank statistics with paired survival data , 2008, Statistics in medicine.

[33]  Toshimitsu Hamasaki,et al.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints. , 2013, Biostatistics.

[34]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[35]  N L Geller,et al.  The analysis of multiple endpoints in clinical trials. , 1987, Biometrics.

[36]  R J Cook,et al.  Guidelines for monitoring efficacy and toxicity responses in clinical trials. , 1994, Biometrics.

[37]  Guosheng Yin,et al.  Clinical Trial Design: Bayesian and Frequentist Adaptive Methods , 2011 .

[38]  H M James Hung,et al.  Statistical Considerations for Testing Multiple Endpoints in Group Sequential or Adaptive Clinical Trials , 2007, Journal of biopharmaceutical statistics.

[39]  John M. Lachin,et al.  Interim analyses with repeated measurements in a sequential clinical trial , 1990 .

[40]  Ross L. Prentice,et al.  On assessing the strength of dependency between failure time variates , 1996 .

[41]  A. Shiryaev,et al.  Limit Theorems for Stochastic Processes , 1987 .

[42]  Susan Halabi.  Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints. , 2012, Journal of biometrics & biostatistics.

[43]  Tze Leung Lai,et al.  Weak Convergence of Time-Sequential Censored Rank Statistics with Applications to Sequential Testing in Clinical Trials , 1991 .

[44]  Michael R Kosorok,et al.  Design and Analysis of Group Sequential Clinical Trials with Multiple Primary Endpoints , 2004, Biometrics.

[45]  Tze Leung Lai,et al.  Power, sample size and adaptation considerations in the design of group sequential clinical trials , 2003 .

[46]  John M. Lachin,et al.  Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations , 1984 .

[47]  Danyu Lin,et al.  Nonparametric sequential testing in clinical trials with incomplete multivariate observations , 1991 .